Biopharmaceutical group Arecor Therapeutics plc (AIM: AREC) announced on Wednesday that it presented promising Phase I trial results for its ultra-concentrated, ultra-rapid acting insulin, AT278, at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid.
The trial, conducted at the Medical University of Graz and Joanneum Research in Austria, demonstrated that AT278 (500 U/mL) outperforms NovoRapid (100 U/mL) in terms of glucose-lowering effects in Type 2 diabetes patients with high BMI.
AT278 showed a 1.7-fold higher glucose-lowering effect within the first 60 minutes compared to NovoRapid (p
Imugene announces Azer-cel Phase 1b clinical trial data
CARsgen successfully defends European GPC3 CAR-T patent
IGI and AbbVie enter global licensing agreement for ISB 2001
PharmaJet signs MOU with Egyptian UPA and EVA Pharma to introduce needle-free vaccine delivery
Zhimeng Biopharma's CB03-154 ALS Phase 2/3 study receives Chinese clinical trial approval
Taiho Oncology and Taiho Pharmaceutical's INQOVI/venetoclax combination sNDA accepted by US FDA
SciBase introduces Nevisense pilot at Florida research university
Exact Sciences secures Medicare coverage for Oncodetect MRD test in colorectal cancer
Tyra Biosciences to announce TYRA-300 preclinical results at ENDO 2025
Centivax raises USD45m to commercialise universal flu vaccine
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Avenzo Therapeutics doses first patient in AVZO-1418/DB-1418 Phase 1/2 clinical study